Home Cart Sign in  
Chemical Structure| 691868-88-9 Chemical Structure| 691868-88-9

Structure of RO8191
CAS No.: 691868-88-9

Chemical Structure| 691868-88-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RO8191 is an orally active interferon (IFN) receptor agonist that binds to IFNAR2 and activates the expression of interferon-stimulated genes (ISGs). It exhibits significant antiviral activity against HCV and HBV, suitable for antiviral treatment research.

Synonyms: CDM-3008

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RO8191

CAS No. :691868-88-9
Formula : C14H5F6N5O
M.W : 373.21
SMILES Code : FC(C1=CC(C(F)(F)F)=NC2=C1C=CC3=NC(C4=NN=CO4)=CN32)(F)F
Synonyms :
CDM-3008
MDL No. :MFCD03102493
InChI Key :GRHYZVJEXKTJOS-UHFFFAOYSA-N
Pubchem ID :2768133

Safety of RO8191

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Related Pathways of RO8191

JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HeLa cells 0.01-100 µM 1 day CDM-3008 showed anti-SARS-CoV-2 activity in HeLa cells with an IC50 of 0.78 μM Int J Mol Sci. 2021 Oct 28;22(21):11641
NCI-H1395 cells 2 µM 24 hours RO8191 treatment slowed down the changes induced by Amuc_1100, inhibiting the recruitment and toxicity of CD8+ T cells. Microb Biotechnol. 2024 Jul;17(7):e14522
A549 cells 2 µM 24 hours RO8191 treatment slowed down the changes induced by Amuc_1100, inhibiting the recruitment and toxicity of CD8+ T cells. Microb Biotechnol. 2024 Jul;17(7):e14522
Calu-3 cells 0.001-10 µM 3 days CDM-3008 showed anti-SARS-CoV-2 activity in Calu-3 cells with an IC50 of 2.54 μM Int J Mol Sci. 2021 Oct 28;22(21):11641
N2a-58 cells 0.5, 5, 50, 250, 500 µM 48 hours RO8191 treatment did not alter PrPC levels in N2a-58 cells but dose-dependently increased OAS1a expression. Brain. 2019 Apr 1;142(4):1035-1050
N2a-22L cells 0.5, 5, 50, 250, 500 µM 48 hours RO8191 treatment significantly reduced PrPSc levels in N2a-22L cells in a dose-dependent manner. Brain. 2019 Apr 1;142(4):1035-1050
REP-HepG2-NTCP cells 1 and 10 µM 9 days Evaluated the anti-HBV effect of CDM-3008, showing significant reduction in HBV DNA levels Cell Death Discov. 2021 Jun 2;7(1):130

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Myocardial infarction model Intragastric administration 10 mg/kg Single dose 30 min before MI surgery To assess the effect of RO8191 on the anti-inflammatory and cardiac reparative effects of hEPs in MI treatment, showing that RO8191 attenuated these beneficial effects of hEPs. Adv Sci (Weinh). 2023 Sep;10(27):e2300470
C57BL/6 mice Subcutaneous allograft tumour model Intraperitoneal injection 2 mg/kg Not specified RO8191 attenuated the inhibitory effect of Amuc_1100 on tumour growth and reduced the number of tumour-infiltrating CD8+ T cells. Microb Biotechnol. 2024 Jul;17(7):e14522
ICR mice LPS-induced acute lung injury model In vitro 2 μM Not used Partially reversed the inhibitory effects of IRD on inflammation J Inflamm Res. 2021 Feb 5;14:341-354.
DdY mice 22L prion infection model Intraperitoneal injection 2.0 mg/kg/day Administered every other day starting from 2 days post-inoculation until sacrifice RO8191 treatment significantly prolonged the survival of infected mice and reduced PrPSc levels and pathological changes in the brain and spleen. Brain. 2019 Apr 1;142(4):1035-1050
Rats Post-LT liver fibrosis model Oral 20 mg/kg Daily for 10 days To study the effect of RO8191 on liver fibrosis, results showed RO8191 increased the stage of liver fibrosis and the levels of COL1A1 and ACTA2. Stem Cell Res Ther. 2025 May 1;16(1):217

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.68mL

0.54mL

0.27mL

13.40mL

2.68mL

1.34mL

26.79mL

5.36mL

2.68mL

 

Historical Records

Categories